SCHEMBL4019783

SCHEMBL4019783

CCOC(=O)C(=O)N(Cc1cccc(C(F)(F)F)c1)Cc1ccc(S(=O)(=O)NCCCC(=O)O)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.40
THRB P10828 1/20 0.37
NR3C1 P04150 1/20 0.37
S1PR4 O95977 1/20 0.37
S1PR5 Q9H228 1/20 0.37
PTGES O14684 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
S1PR1 P21453 2/20 0.36
S1PR3 Q99500 2/20 0.36
FFAR4 Q5NUL3 3/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024326 0.89 MAPK1 (0.46) MAPK1SMN1; SMN2TSHRNR3C1S1PR4
SCHEMBL4022476 0.88 SMN1; SMN2 (0.43) MAPK1SMN1; SMN2TSHRMAPTLMNA
SCHEMBL4016045 0.83 SMN1; SMN2 (0.42) SMN1; SMN2TSHRNR3C1PTGESS1PR1
SCHEMBL1854854 0.83 SMN1; SMN2 (0.42) SMN1; SMN2TSHRNR3C1PTGESS1PR1
SCHEMBL1855560 0.82 SMN1; SMN2 (0.42) MAPK1SMN1; SMN2TSHRNPSR1S1PR1
SCHEMBL1852856 0.80 SMN1; SMN2 (0.46) MAPK1SMN1; SMN2TSHRMAPTALDH1A1
SCHEMBL4711323 0.78 SMN1; SMN2 (0.40) MAPK1SMN1; SMN2TSHRTHRBS1PR4
SCHEMBL1852522 0.77 TRPM8 (0.43) SMN1; SMN2NR3C1PTGESNPSR1LMNA
SCHEMBL1852016 0.76 SERPINE1 (0.42) SMN1; SMN2TSHRNR3C1PTGESKDM4E
SCHEMBL4022922 0.76 EPHX1 (0.39) SMN1; SMN2TSHRPTGESNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 MAPK1 2747/4885SMN1; SMN2 2147/4885TSHR 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.